Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Prevention of recurrent variceal hemorrhage in patients with cirrhosis

Arun J Sanyal, MD
Jasmohan S Bajaj, MD
Section Editor
Bruce A Runyon, MD
Deputy Editor
Kristen M Robson, MD, MBA, FACG


The natural history of cirrhosis following an episode of variceal hemorrhage has been defined from clinical trials in which "control" subjects did not receive any specific treatment to prevent rebleeding. The cumulative data indicate that over 70 percent of patients experience recurrent variceal hemorrhage within one year of their index bleeding episode [1,2]. The risk of rebleeding is greatest immediately after cessation of active bleeding and then declines, reaching close to baseline values by six weeks. Approximately 70 percent of all untreated patients die within the first year after their initial variceal hemorrhage. The causes of death include recurrent variceal hemorrhage, liver failure, hepatic encephalopathy, and progressive ascites and infections.

These data underscore the importance of preventing recurrent hemorrhage, sustaining liver function, maintaining an ascites-free state, and avoiding infections to achieve prolonged survival. At this time, orthotopic liver transplant (OLT) is the only treatment that achieves all of these objectives and prolongs long-term survival with any degree of certainty. However, some patients are not suitable subjects for liver transplants and, even when OLT is being considered, patients often have to wait several months before an organ becomes available. During this time, they are at risk for recurrent variceal hemorrhage and therefore require treatment to prevent this complication. (See "Liver transplantation in adults: Patient selection and pretransplantation evaluation".)

The ideal treatment would be one that is universally effective, safe, freely available, easy to administer and inexpensive. Because such a treatment does not exist, the choice of a given modality of treatment over another involves consideration of its relative efficacy and safety, availability, and cost considerations. The major options are endoscopic sclerotherapy, endoscopic band ligation, pharmacologic therapy with beta blockers and oral nitrates, insertion of a transjugular intrahepatic portosystemic shunt, and surgery.

This topic with will review the options for preventing recurrent variceal hemorrhage in patients with cirrhosis. The treatment of acute variceal hemorrhage is discussed elsewhere. (See "General principles of the management of variceal hemorrhage" and "Methods to achieve hemostasis in patients with acute variceal hemorrhage" and "Endoscopic variceal ligation".)


The American Association for the Study of Liver Diseases (AASLD) issued guidelines in 2007 for the prevention of variceal recurrent bleeding [3]. The approaches recommended by the guidelines (nonselective beta blockers, endoscopic variceal ligation, transjugular intrahepatic portosystemic shunts, and liver transplantation), as well as other options for the prevention of recurrent variceal bleeding, are discussed in detail below. The recommendations in the AASLD guidelines are similar to those in a 2015 international consensus statement (Baveno VI) [4] and in 2015 guidelines from the British Society of Gastroenterology [5].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Dec 15, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800.
  2. Burroughs AK. The natural history of varices. J Hepatol 1993; 17 Suppl 2:S10.
  3. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.
  4. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743.
  5. Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64:1680.
  6. MacDougall BR, Westaby D, Theodossi A, et al. Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet 1982; 1:124.
  7. Söderlund C, Ihre T. Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment. Acta Chir Scand 1985; 151:449.
  8. Terblanche J, Bornman PC, Kahn D, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial. Lancet 1983; 2:1328.
  9. Copenhagen Esophageal Varices Sclerotherapy Project. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. N Engl J Med 1984; 311:1594.
  10. Westaby D, Macdougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985; 5:827.
  11. Korula J, Balart LA, Radvan G, et al. A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy. Hepatology 1985; 5:584.
  12. Kochhar R, Goenka MK, Mehta SK. Esophageal strictures following endoscopic variceal sclerotherapy. Antecedents, clinical profile, and management. Dig Dis Sci 1992; 37:347.
  13. Garg PK, Sidhu SS, Bhargava DK. Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study. Dig Dis Sci 1995; 40:1569.
  14. Sarin SK, Nanda R, Sachdev G, et al. Intravariceal versus paravariceal sclerotherapy: a prospective, controlled, randomised trial. Gut 1987; 28:657.
  15. Bhargava DK, Singh B, Dogra R, et al. Prospective randomized comparison of sodium tetradecyl sulfate and polidocanol as variceal sclerosing agents. Am J Gastroenterol 1992; 87:182.
  16. Akriviadis E, Korula J, Gupta S, et al. Frequent endoscopic variceal sclerotherapy increases risk of complications. Prospective randomized controlled study of two treatment schedules. Dig Dis Sci 1989; 34:1068.
  17. Sarin SK, Sachdev G, Nanda R, et al. Comparison of the two time schedules for endoscopic sclerotherapy: a prospective randomised controlled study. Gut 1986; 27:710.
  18. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280.
  19. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081.
  20. Lo GH, Lai KH, Cheng JS, et al. The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: a prospective, randomized trial. Hepatology 1998; 28:391.
  21. Pagliaro L, D'Amico G, Sörensen TI, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117:59.
  22. Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4:355.
  23. Cerbelaud P, Lavignolle A, Perrin D, et al. Propranolol et prevention des recidives des ruptures de varice oesophagienne du cirrhotique. Gastroenterol Clin Biol 1986; 10:18A.
  24. Colman J, Jones P, Finch C, et al. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients. Hepatology 1990; 12:851.
  25. Colombo M, de Franchis R, Tommasini M, et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology 1989; 9:433.
  26. Gatta A, Merkel C, Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion 1987; 37:22.
  27. Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986; 6:1239.
  28. Garden OJ, Mills PR, Birnie GG, et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology 1990; 98:185.
  29. Sheen IS, Chen TY, Liaw YF. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver 1989; 9:1.
  30. Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989; 298:1363.
  31. Queuniet AM, Czernichow P, Lerebours E, et al. [Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients]. Gastroenterol Clin Biol 1987; 11:41.
  32. Marbet UA, Straumann A, Gyr KE, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scand J Gastroenterol 1988; 23:369.
  33. Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336:153.
  34. Pérez-Ayuso RM, Piqué JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991; 337:1431.
  35. Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 7:447.
  36. Valla D, Jiron MI, Poynard T, et al. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5:144.
  37. Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991; 12:124.
  38. Feu F, García-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056.
  39. Raines DL, Dupont AW, Arguedas MR. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding. Aliment Pharmacol Ther 2004; 19:571.
  40. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60:643.
  41. Koshy A, Girod C, Lee SS, et al. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats. Hepatology 1989; 9:269.
  42. Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017.
  43. Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010; 52:811.
  44. Bendtsen F, Henriksen JH, Sørensen TI. Long-term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol 1991; 26:933.
  45. Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482.
  46. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439.
  47. Zipprich A, Garcia-Tsao G, Seufferlein T, et al. The presence of esophageal varices (EV), but not treatement with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascites. Hepatology 2011; 54:461A.
  48. Bossen L, Krag A, Vilstrup H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology 2016; 63:1968.
  49. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther 2013; 38:407.
  50. Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008; 149:109.
  51. Ravipati M, Katragadda S, Swaminathan PD, et al. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc 2009; 70:658.
  52. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362:823.
  53. Merkel C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26:34.
  54. Villanueva C, Balanzó J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:1624.
  55. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31:1239.
  56. Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647.
  57. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123:728.
  58. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123:1013.
  59. García-Pagán JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009; 58:1144.
  60. Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009; 137:892.
  61. Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology 2002; 123:1388.
  62. Qureshi H, Zuberi SJ, Alam E. Efficacy of oral propranolol and injection sclerotherapy in the long-term management of variceal bleeding. Digestion 1990; 46:193.
  63. Rossi V, Calès P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991; 12:283.
  64. Andreani T, Poupon RE, Balkau GB, et al. Etude controlee. Gastroenterol Clin Biol 1991; 15(Suppl):A215.
  65. Alexandrino PT, Alves MM, Pinto Correia J. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial. J Hepatol 1988; 7:175.
  66. Dasarathy S, Dwivedi M, Bhargava DK, et al. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. Hepatology 1992; 16:89.
  67. Dollet JM, Champigneulle B, Patris A, et al. [Endoscopic sclerotherapy versus propranolol after hemorrhage caused by rupture of esophageal varices in patients with cirrhosis. Results of a 4-year randomized study]. Gastroenterol Clin Biol 1988; 12:234.
  68. Fleig WE, Stange EF, Hunecke R, et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 1987; 7:355.
  69. Martin T, Taupignon A, Lavignolle A, et al. [Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy]. Gastroenterol Clin Biol 1991; 15:833.
  70. Terés J, Bosch J, Bordas JM, et al. Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. Gastroenterology 1993; 105:1508.
  71. Westaby D, Polson RJ, Gimson AE, et al. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology 1990; 11:353.
  72. Pagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomized controlled trials: Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2:71.
  73. Ferayorni, L, Polio, et al. Drug therapy for portal hypertension: A 5 year review. In: Portal hypertension II: Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, DeFranchis, R (Eds), Blackwell Science, Oxford 1996. p.68.
  74. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332.
  75. Bernard B, Lebrec D, Mathurin P, et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997; 26:312.
  76. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:849.
  77. Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26:1115.
  78. Pomier-Layrargues G, Villeneuve JP, Deschênes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001; 48:390.
  79. Merli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998; 27:48.
  80. Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110:832.
  81. Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:858.
  82. Sauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113:1623.
  83. García-Villarreal L, Martínez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29:27.
  84. Rössle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349:1043.
  85. Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.
  86. Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis 1996; 16:315.
  87. Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30:612.
  88. Escorsell A, Bañares R, García-Pagán JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35:385.
  89. García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370.
  90. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.
  91. Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.
  92. Bureau C, Garcia Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.
  93. Cello JP, Grendell JH, Crass RA, et al. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. N Engl J Med 1984; 311:1589.
  94. Cello JP, Grendell JH, Crass RA, et al. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. N Engl J Med 1987; 316:11.
  95. Henderson JM, Kutner MH, Millikan WJ Jr, et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective, randomized trial. Ann Intern Med 1990; 112:262.
  96. Terés J, Baroni R, Bordas JM, et al. Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987; 4:159.
  97. Kitano S, Iso Y, Hashizume M, et al. Sclerotherapy vs. esophageal transection vs. distal splenorenal shunt for the clinical management of esophageal varices in patients with child class A and B liver function: a prospective randomized trial. Hepatology 1992; 15:63.
  98. Rikkers LF, Jin G, Burnett DA, et al. Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. Am J Surg 1993; 165:27.
  99. Garrett KO, Reilly JJ Jr, Schade RR, van Thiel DH. Bleeding esophageal varices: treatment by sclerotherapy and liver transplantation. Surgery 1988; 104:819.
  100. Bismuth H, Adam R, Raccuia JS. [Liver transplantation in the treatment strategy of portal hypertension]. Chirurg 1995; 66:574.
  101. Esquivel CO, Klintmalm G, Iwatsuki S, et al. Liver transplantation in patients with patent splenorenal shunts. Surgery 1987; 101:430.
  102. Shaked A, Goldstein RM, Klintmalm GB, et al. Portosystemic shunt versus orthotopic liver transplantation for the Budd-Chiari syndrome. Surg Gynecol Obstet 1992; 174:453.
  103. Targownik LE, Spiegel BM, Dulai GS, et al. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol 2004; 99:1306.
  104. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345:669.